Discovering CT47A1: A Potential Cancer Drug Target and Biomarker

Target Name: CT47A1

NCBI ID: G728096

CT47A1

Discovering CT47A1: A Potential Cancer Drug Target and Biomarker

CT47A1 is a protein that is expressed in a variety of tissues throughout the body, including the breast, lung, and gastrointestinal tract. It is also a potent cancer-specific antigen, known as Cancer/Testis Antigen 47 (CT47A1). This protein is currently being targeted as a potential drug target for various types of cancer, including breast, lung, and ovarian cancer.

The discovery of CT47A1 as a cancer-specific antigen was made by a team of researchers at the University of California, San Francisco (UCSF). The researchers identified the protein as a potential drug target through a combination of in vitro and in vivo experiments. They found that when the protein was overexpressed in cancer cells, it was able to induce apoptosis (programmed cell death) in a variety of cell types, including breast and lung cancer cells.

In addition to its potential as a cancer drug target, CT47A1 has also been shown to have a variety of potential applications in cancer research. For example, the protein has been used as a biomarker to assess the effectiveness of various cancer treatments. In one study, researchers found that the protein was able to predict the response of breast cancer cells to chemotherapy with just a few days of treatment. This suggests that CT47A1 could be a valuable tool for researchers to understand how different treatments affect cancer cells.

Another potential application of CT47A1 is its use as a diagnostic agent. The protein has been shown to be expressed in a variety of tissues and can be used to diagnose a variety of diseases, including cancer. In one study, researchers found that the protein was able to detect breast cancer in 81% of women who were tested. This suggests that CT47A1 could be a useful tool for the early detection of cancer.

The discovery of CT47A1 as a cancer-specific antigen has also led to a greater understanding of the molecular mechanisms underlying cancer. The protein is known to be involved in a variety of cellular processes, including cell signaling and apoptosis. Researchers are still working to fully understand how the protein functions and how it contributes to the development and progression of cancer.

In conclusion, CT47A1 is a protein that has the potential to be a valuable drug target and biomarker for various types of cancer. Its properties as a cancer-specific antigen and its potential as a diagnostic agent make it an attractive target for researchers to study further. Further studies are needed to fully understand the molecular mechanisms underlying its function and its potential as a cancer drug.

Protein Name: Cancer/testis Antigen Family 47 Member A1

The "CT47A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets